. Author manuscript; available in PMC: 2018 Dec 1.

Published in final edited form as: J Pediatr Gastroenterol Nutr. 2017 Dec;65(6):639–645. doi: 10.1097/MPG.0000000000001620

Table 1. Patient Characteristics (n = 34).

	Median or No.	IQR	Min, Max
Age, years	14.9	13.2 – 15.9	5, 17.9
Weight, kg	53	48 – 62	22, 120
Female, n (%)	13 (38%)	-	-
Time since diagnosis, years	1.9	1.1 – 2.9	0.3, 7.6
Time since start of IFX, wk	29.7	13.9 – 56.1	2.0 - 174
Albumin, g/dL	4.3	4.0 – 4.5	3.4, 4.8
CRP, mg/L	2.4	0.9 – 4.8	0.2, 18.4
Concomitant immunomodulation, n (%)	15 (44%)	-	-
Detectable ATI, n (%)	4 (12%)	-	-

IQR, interquartile range; IFX, infliximab; CRP, c-reactive protein; ATI, antibodies to infliximab; Concomitant immunomodulation refers to purine-analogue or methotrexate.